IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 239 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,596,809 | -38.6% | 1,230,068 | -5.0% | 0.00% | 0.0% |
| Q2 2023 | $9,112,161 | +4.1% | 1,294,341 | -9.7% | 0.00% | 0.0% |
| Q1 2023 | $8,754,231 | +16.0% | 1,432,771 | +21.4% | 0.00% | 0.0% |
| Q4 2022 | $7,543,599 | +18.5% | 1,180,532 | +77.6% | 0.00% | 0.0% |
| Q3 2022 | $6,368,000 | +83.3% | 664,616 | +111.2% | 0.00% | – |
| Q2 2022 | $3,474,000 | -79.6% | 314,646 | -69.2% | 0.00% | -100.0% |
| Q1 2022 | $17,035,000 | +12.8% | 1,023,206 | +29.4% | 0.00% | +100.0% |
| Q4 2021 | $15,097,000 | +10.1% | 790,884 | +42.2% | 0.00% | 0.0% |
| Q3 2021 | $13,712,000 | +14.4% | 556,070 | +20.7% | 0.00% | 0.0% |
| Q2 2021 | $11,985,000 | -85.5% | 460,590 | -82.3% | 0.00% | -88.9% |
| Q1 2021 | $82,516,000 | -44.5% | 2,606,356 | -18.6% | 0.01% | -52.6% |
| Q4 2020 | $148,595,000 | +39.7% | 3,202,468 | -0.9% | 0.02% | +35.7% |
| Q3 2020 | $106,386,000 | +18.9% | 3,231,645 | -0.9% | 0.01% | 0.0% |
| Q2 2020 | $89,503,000 | -7.0% | 3,260,588 | +1.4% | 0.01% | -17.6% |
| Q1 2020 | $96,211,000 | +9.3% | 3,214,019 | +1.1% | 0.02% | +30.8% |
| Q4 2019 | $87,998,000 | +54.2% | 3,179,139 | +1.4% | 0.01% | +62.5% |
| Q3 2019 | $57,064,000 | -24.5% | 3,135,403 | +1.7% | 0.01% | -27.3% |
| Q2 2019 | $75,627,000 | +282.0% | 3,084,339 | +48.2% | 0.01% | +266.7% |
| Q1 2019 | $19,799,000 | +75.2% | 2,081,839 | +63.0% | 0.00% | +50.0% |
| Q4 2018 | $11,302,000 | +2155.9% | 1,277,035 | +2771.2% | 0.00% | – |
| Q3 2018 | $501,000 | -75.8% | 44,477 | -72.5% | 0.00% | – |
| Q2 2018 | $2,070,000 | +159.4% | 161,657 | +242.5% | 0.00% | – |
| Q1 2018 | $798,000 | +90.9% | 47,198 | -9.6% | 0.00% | – |
| Q4 2017 | $418,000 | +190.3% | 52,224 | +180.4% | 0.00% | – |
| Q3 2017 | $144,000 | +97.3% | 18,622 | +88.4% | 0.00% | – |
| Q2 2017 | $73,000 | – | 9,885 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |